Cyteir Therapeutics Inc. (CYT)
NASDAQ: CYT
· Real-Time Price · USD
3.02
-0.07 (-2.27%)
At close: Mar 15, 2024, 9:00 PM
Cyteir Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 100K | 100K | 308K | 326K | 200K | 200K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -100K | -100K | -308K | -326K | -200K | -200K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -5.17M | -9.61M | -13.42M | -10.05M | -11.76M | -12.23M | -14.13M | -11.86M | -11.75M | -11.31M | -7.34M |
Interest Income | 1.64M | 1.2M | 1.54M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -3.53M | -8.4M | -12.49M | -8.79M | -11.04M | -12.12M | -14.1M | -11.81M | -11.7M | -11.29M | -7.31M |
Net Income | -3.53M | -8.4M | -11.55M | -7.4M | -10.33M | -12.02M | -14.07M | -11.81M | -11.7M | -11.29M | -7.31M |
Selling & General & Admin | 2.5M | 4.2M | 4.11M | 2.58M | 3.49M | 3.43M | 4.04M | 3.61M | 3.55M | 2.42M | 1.72M |
Research & Development | 2.68M | 5.4M | 9.31M | 7.47M | 8.27M | 8.79M | 10.09M | 8.26M | 8.21M | 8.89M | 5.61M |
Other Expenses | n/a | n/a | n/a | 1.26M | 714K | 106K | 29K | 47K | 48K | 13K | 25K |
Operating Expenses | 5.17M | 9.61M | 13.42M | 10.05M | 11.76M | 12.23M | 14.13M | 11.86M | 11.75M | 11.31M | 7.34M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.17M | 9.61M | 13.42M | 10.05M | 11.76M | 12.23M | 14.13M | 11.86M | 11.75M | 11.31M | 7.34M |
Income Tax Expense | n/a | n/a | -936K | -1.4M | -714K | -106K | -29K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 36.03M | 35.74M | 35.59M | 35.38M | 35.33M | 35.28M | 35.24M | 35.14M | 35.06M | 34.76M | 34.47M |
Shares Outstanding (Diluted) | 36.03M | 35.74M | 35.59M | 35.38M | 35.33M | 35.28M | 35.24M | 35.14M | 35.06M | 34.76M | 34.47M |
EPS (Basic) | -0.1 | -0.24 | -0.32 | -0.21 | -0.29 | -0.34 | -0.4 | -0.34 | -0.33 | -0.32 | -0.21 |
EPS (Diluted) | -0.1 | -0.24 | -0.32 | -0.21 | -0.29 | -0.34 | -0.4 | -0.34 | -0.33 | -0.32 | -0.21 |
EBITDA | -5.06M | -9.5M | -13.42M | -9.88M | -11.59M | -12.06M | -13.97M | -11.86M | -11.63M | -11.2M | -7.23M |
EBIT | -5.17M | -9.61M | n/a | -8.83M | -11.76M | -12.23M | -14.13M | n/a | -11.75M | -11.31M | -7.34M |
Depreciation & Amortization | 110K | 108K | 607K | 170K | 170K | 169K | 159K | 140K | 125K | 111K | 103K |